A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

Federation Francophone de Cancerologie Digestive150 enrolled

Overview

The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.

The aim is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Hepatocholangiocarcinoma Fibrolamellar Carcinoma Hepatic Epithelioid Hemangioendothelioma Hepatoblastoma Hepatic Neuroendocrine Carcinoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years of age or older, * with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma * diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort * for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies. Exclusion Criteria: * without social security * No access to tumor block

Locations (40)

CHU Amiens picardie

Amiens, France

RECRUITING

Chu Angers

Angers, France

RECRUITING

Ch - Centresimone Veil de Beauvais

Beauvais, France

RECRUITING

Chu Jean Minjoz

Besançon, France

Outcomes

Primary Outcomes

Description of the clinical, histological and radiological characteristics of various rare primary liver cancers

Time frame: up to 5 years from the date of diagnosis

Secondary Outcomes

Recurrence-free survival (for non-metastatic patients)

Time interval between the date of disease diagnosis and the date of locoregional and/or metastatic recurrence or death (all causes). Patients alive and without recurrence will be censored at the date of last news

Time frame: up to 5 years from diagnosis

Progression-free survival (for metastatic patients)

Time interval between the date of diagnosis of the disease and the date of radiological and/or clinical progression or death (all causes). Patients alive and progression-free will be censored at the date of last news.

Time frame: up to 5 years from diagnosis

Overall survival

Time interval between the date of diagnosis of the disease and the date of death (from all causes). Living patients will be censored at the date of last news.

Time frame: up to 5 years from diagnosis

A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

Overview

Conditions

Eligibility

Locations (40)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts